Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx’s Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun

By Adam J. Fein, Ph.D. Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque: Why Optum Rx Is Accelerating Its Transparency Strategy The Most Important 340B Paper You’ll Ever Read Blue Shield of California’s PBM Unbundling Plan Meets Reality Prior Authorization: Administrative Complexity = Delayed Care Plus: The Drug Channels Institute team takes on Las Vegas—with stickers! P.S. Join my 70,000+ LinkedIn followers for links to interesting industry news, along with unfiltered commentary from the DCI community. 340B in 2026: Market Shifts, Policy Battles, and…

By Adam J. Fein, Ph.D.

Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque:

Why Optum Rx Is Accelerating Its Transparency Strategy

The Most Important 340B Paper You’ll Ever Read

Blue Shield of California’s PBM Unbundling Plan Meets Reality

Prior Authorization: Administrative Complexity = Delayed Care

Plus: The Drug Channels Institute team takes on Las Vegas—with stickers!

P.S. Join my 70,000+ LinkedIn followers for links to interesting industry news, along with unfiltered commentary from the DCI community.

340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders.

Don't miss DCI’s upcoming webinar on Friday, June 12, 2026, from 12:00 p.m. to 1:30 p.m. ET. Adam J. Fein and Tyler Novotny will unpack the good, the bad, and the ugly of the 340B program—and what it means for you. Click here to learn more and sign up.